ArticleOncology letters2023
Prostate biopsy approach and complication rates.
Article in Oncology letters, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Characterizing the Diffusion Properties of Prostate Tissue Using Paired MR Microscopy and Multidimensional Diffusion MRI.Magnetic resonance in medicine · 2026Article
- Infection rates of trans-perineal versus trans-rectal prostate biopsy: A Middle Eastern tertiary center experience-Time for a change?Arab journal of urology · 2026Article
- Povidone-iodine for transrectal prostate biopsy.The Cochrane database of systematic reviews · 2025Article
- To biopsy or not biopsy, that is the question - PI-RADS 3 prostate lesions - validation of clinical and radiological parameters for biopsy decision-making.BMC urology · 2025Article
- Antibiotic prophylaxis for transperineal prostate biopsy.The Cochrane database of systematic reviews · 2025Article
- An overview of utilizing artificial intelligence in localized prostate cancer imaging.Expert review of medical devices · 2025Review
- A case report of urethral corpus cavernosum pseudoaneurysm formation after ultrasound-guided transperineal prostate biopsy.BMC urology · 2025Article
- Untargeted metabolomics revealed urinary metabolic pattern for discriminating prostate cancer from benign prostatic hyperplasia in Chinese participants.Frontiers in oncology · 2025Article
- Analysis of biopsy pathology and risk factors of lymph node metastasis in prostate cancer.International urology and nephrology · 2024Article
- Transrectal Prostate Biopsy Approach in Men Undergoing Kidney Transplant: A Retrospective Cohort Study at Three Referral Academic Centers.Diagnostics (Basel, Switzerland) · 2024Article
- Evaluating the Effectiveness and Safety of Robotic-Assisted MRI/TRUS Fusion Transperineal Prostate Biopsy Systems: A Narrative Review Based on Current Literature.The Eurasian journal of medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prostate biopsy is the gold standard to confirm prostate cancer. In addition to standard 12-core biopsies, magnetic resonance imaging (MRI)-guided prostate biopsies have recently been introduced to improve the detection of clinically significant prostate cancer. The present study aimed to compare the complications after standard transrectal ultrasound-guided and standard plus targeted (MRI-guided) prostate biopsies, to study the impact of the number of biopsy cores on complication rates, and to compare complication rates after transrectal ultrasound-guided prostate biopsies with those following transperineal prostate biopsies from the literature. A prospective study was performed, which included 135 patients who underwent transrectal ultrasound-guided prostate biopsies between April 1 and June 30, 2022, at the Urology Department of the University Hospital of Pointe à Pitre (Pointe à Pitre, Guadeloupe). A total of 51 patients were excluded because of missing information concerning their post-biopsy surveillance. The median age at the time of biopsy was 69 years, median prostate-specific antigen value was 8.9 ng/ml, median prostate volume was 57.5 ml, and median number of cores was 15. A total of 35 of the 84 included patients (41.7%) had a standard biopsy only and 49 (58.3%) had targeted (MRI-guided) plus standard biopsies. A total of 53 patients (63.1%) experienced early side effects, whereas only 24 patients (28.6%) experienced late side effects. Three patients (3.6%) required hospitalization for post-biopsy complications. Early side effects, especially hematuria and hematospermia, occurred significantly more frequently in the targeted plus standard group, with more cores taken, with no significant difference concerning late side effects or infectious complications between the standard and standard plus targeted groups. The admission rate for sepsis after transperineal biopsy has been reported to vary between 0 and 1%, whereas the present study had an admission rate of 2.29% using the transrectal approach. Further studies are required to analyze the complications requiring hospitalization after transrectal and transperineal biopsies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.